S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
S&P 500   4,577.11 (-1.84%)
DOW   35,368.47 (-1.51%)
QQQ   370.55 (-2.49%)
AAPL   169.80 (-1.89%)
MSFT   302.65 (-2.43%)
FB   318.15 (-4.14%)
GOOGL   2,719.96 (-2.50%)
AMZN   3,178.35 (-1.99%)
TSLA   1,030.51 (-1.82%)
NVDA   259.03 (-3.86%)
BABA   128.60 (-2.26%)
NIO   29.61 (-4.33%)
AMD   131.93 (-3.62%)
CGC   7.78 (-7.38%)
MU   92.87 (-4.61%)
GE   102.89 (-0.26%)
T   27.31 (+0.48%)
F   24.38 (-3.22%)
DIS   152.27 (+0.22%)
AMC   18.84 (-8.41%)
PFE   54.11 (-1.53%)
ACB   5.11 (-7.26%)
BA   225.01 (-0.42%)
NASDAQ:NYMX

Nymox Pharmaceutical Stock Forecast, Price & News

$1.73
+0.13 (+8.13%)
(As of 01/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.60
▼
$1.75
50-Day Range
$0.95
▼
$1.79
52-Week Range
$0.94
▼
$3.50
Volume
189,678 shs
Average Volume
156,692 shs
Market Capitalization
$146.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.44
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive NYMX News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.


Nymox Pharmaceutical logo

About Nymox Pharmaceutical

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Headlines

Insiders at Nymox Pharmaceutical Corporation (NASDAQ:NYMX) recouped some losses this week after buying this year, still down US$31k
January 3, 2022 |  nasdaq.com
Nymox Pharmaceutical Corp Shares Near 52-Week Low - Market Mover
December 31, 2021 |  nasdaq.com
Nymox Shareholder Update
December 13, 2021 |  finance.yahoo.com
NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference
November 15, 2021 |  finance.yahoo.com
NYMOX Provides Current Update
October 11, 2021 |  finance.yahoo.com
Lennham Pharmaceuticals Expands Leading Psilocybin Patent Portfolio with Addition of New Patent Family
September 11, 2021 |  au.finance.yahoo.com
NYMOX Provides Shareholder Update
September 10, 2021 |  finance.yahoo.com
Nymox Pharmaceutical Corporation Common Stock (Bahamas) (NYMX)
August 2, 2021 |  nasdaq.com
Who Has Been Buying Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Shares?
July 27, 2021 |  finance.yahoo.com
Nymox Announces Date for Fexapotide Filing
May 6, 2021 |  finance.yahoo.com
Do Insiders Own Lots Of Shares In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)?
April 30, 2021 |  ca.finance.yahoo.com
Nymox Announces $8,000,000 Private Placement
April 28, 2021 |  finance.yahoo.com
Nymox Provides New Update on Regulatory Activities
March 29, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NYMX
Previous Symbol
CUSIP
N/A
CIK
1018735
Web
www.nymox.com
Phone
(800) 936-9669
Fax
514-332-2227
Employees
3
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
57.67

Profitability

EPS (Most Recent Fiscal Year)
($0.15)
Net Income
$-11.74 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-558.19%
Return on Assets
-288.11%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.86
Quick Ratio
1.84

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
84,496,000
Free Float
38,868,000
Market Cap
$146.18 million
Optionable
Optionable

Company Calendar

Last Earnings
11/12/2021
Today
1/18/2022
Next Earnings (Estimated)
4/04/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.21 out of 5 stars

Medical Sector

1200th out of 1,414 stocks

Diagnostic Substances Industry

20th out of 25 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Nymox Pharmaceutical (NASDAQ:NYMX) Frequently Asked Questions

How has Nymox Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Nymox Pharmaceutical's stock was trading at $2.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NYMX shares have decreased by 24.5% and is now trading at $1.73.
View which stocks have been most impacted by COVID-19.

When is Nymox Pharmaceutical's next earnings date?

Nymox Pharmaceutical is scheduled to release its next quarterly earnings announcement on Monday, April 4th 2022.
View our earnings forecast for Nymox Pharmaceutical.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) posted its quarterly earnings data on Friday, November, 12th. The biopharmaceutical company reported ($0.04) EPS for the quarter.
View Nymox Pharmaceutical's earnings history.

Who are Nymox Pharmaceutical's key executives?

Nymox Pharmaceutical's management team includes the following people:
  • Paul Averback, Chairman, President & Chief Executive Officer
  • Randall J. Lanham, COO, Secretary, Director & General Counsel
  • Erik Danielsen, Chief Financial Officer
  • Russell I. Thomson, Vice President-Quality & Regulatory Affairs

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Patriot Financial Group Insurance Agency LLC (0.03%).
View institutional ownership trends for Nymox Pharmaceutical.

Which institutional investors are selling Nymox Pharmaceutical stock?

NYMX stock was sold by a variety of institutional investors in the last quarter, including Patriot Financial Group Insurance Agency LLC.
View insider buying and selling activity for Nymox Pharmaceutical or view top insider-selling stocks.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $1.73.

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical has a market capitalization of $146.18 million. The biopharmaceutical company earns $-11.74 million in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Nymox Pharmaceutical have?

Nymox Pharmaceutical employs 3 workers across the globe.

What is Nymox Pharmaceutical's official website?

The official website for Nymox Pharmaceutical is www.nymox.com.

Where are Nymox Pharmaceutical's headquarters?

Nymox Pharmaceutical is headquartered at BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at [email protected], or via fax at 514-332-2227.


This page was last updated on 1/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.